Inhibikase Therapeutics (IKT) Other Operating Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 4 years of Other Operating Expenses data on file, last reported at $10.0 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 961.47% year-over-year to $10.0 million in Q1 2026; TTM through Mar 2026 was $17.4 million, a 1595.49% increase from a year earlier, with the FY2025 full-year figure at -$1.4 million, changed N/A from the prior year.
• Other Operating Expenses for Q1 2026 stood at $10.0 million, up from $642169.0 in the prior quarter.
• Over the last five years, Other Operating Expenses for IKT reached as high as $10.0 million in Q1 2026 and fell as low as -$10.6 million in Q4 2023.
• Historically, Other Operating Expenses has averaged $945029.0 across 3 years, with a median of $141874.5 in 2025.
• On a YoY basis, Other Operating Expenses climbed as much as 961.47% in 2026 and fell as far as 961.47% in 2026.
• Year by year, Other Operating Expenses stood at -$10.6 million in 2023, then surged by 106.07% to $642169.0 in 2025, then jumped by 1462.66% to $10.0 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $10.0 million in Q1 2026, $642169.0 in Q4 2025, and $7.1 million in Q3 2025.